Exploring the therapeutic potential of interleukin-6 receptor blockade in autoimmune diseases using drug target mendelian randomization
Authors:
- 26 November 2024
- journal article
- research article
- Published by Springer Nature in Immunogenetics
- Vol. 77 (1) , 1-13
Abstract
The blockade of the interleukin 6 receptor (IL-6R) demonstrates significant potential in various autoimmune diseases (ADs); however, the underlying therapeKeywords
Funding Information
- National Natural Science Foundation of China (81601139)
- Natural Science Foundation of Hunan Province (2024JJ5576)
This publication has 50 references indexed in Scilit:
- IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositisJournal of Neuroimmunology, 2006
- Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitisClinical Rheumatology, 2006
- Treatment of Crohn’s disease with anti-IL-6 receptor antibodyJournal of Gastroenterology, 2005
- Interleukin-6 (IL-6) and IGF-IGFBP System in Children and Adolescents with Type 1 Diabetes MellitusExperimental and Clinical Endocrinology & Diabetes, 2004
- Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient miceInternational Journal of Molecular Medicine, 2004
- Anti–interleukin‐6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritisArthritis & Rheumatism, 2003
- Soluble receptors for cytokines and growth factors: generation and biological functionBiochemical Journal, 1994
- Evidence for continuous stimulation of interleukin-6 production in Crohn's diseaseGastroenterology, 1992
- Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice.Journal of Clinical Investigation, 1991
- Molecular cloning and expression of an IL-6 signal transducer, gp130Cell, 1990